3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
17
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
24
Lymphoma
21
Lymphoma, Non-Hodgkin
20
Lymphoma, Large B-Cell, Diffuse
15
Lymphoma, Follicular
12
Neoplasms
8
Leukemia, Lymphocytic, Chronic, B-Cell
8
Lymphoma, Mantle-Cell
7
Lymphoma, B-Cell, Marginal Zone
7
Leukemia, Myeloid, Acute
7
Leukemia
7
Recurrence
6
Lymphoma, Large-Cell, Anaplastic
6
Hodgkin Disease
6
Burkitt Lymphoma
6
Lymphoma, T-Cell, Peripheral
5
Lymphoma, Extranodal NK-T-Cell
5
Myelodysplastic Syndromes
4
Multiple Myeloma
4
Lymphoma, T-Cell
4
Lymphoma, Large-Cell, Immunoblastic
4
Immunoblastic Lymphadenopathy
4
Breast Neoplasms
4
Waldenstrom Macroglobulinemia
3
Sarcoma
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Ovarian Neoplasms
3
Mycosis Fungoides
3
Melanoma
3
Lymphoma, T-Cell, Cutaneous
3
Interventions
Vorinostat
3
Azacitidine
3
venetoclax
2
trametinib
2
ruxolitinib
2
pertuzumab
2
palbociclib
2
olaparib
2
durvalumab
2
dabrafenib
2
copanlisib
2
aflibercept
2
abiraterone
2
Sunitinib
2
Specimen Handling
2
Sirolimus
2
Nivolumab
2
Immunoglobulin G
2
HhAntag691
2
Doxorubicin
2
Disulfides
2
Dasatinib
2
Cyclophosphamide
2
Biopsy
2
Afatinib
2
Ado-Trastuzumab Emtansine
2
2C4 antibody
2
ulixertinib
1
tremelimumab
1
trastuzumab biosimilar HLX02
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Drug Therapy
×
Lymphoid
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled